TAIPEI, Oct. 23, 2026 /PRNewswire/ -- As artificial intelligence (AI) technology continues to advance rapidly, AI is expanding from cloud computing to edge devices, with applications such as intelligent sensing, voice interaction, and visual recognition increasingly being integrated into a wide range of end devices.
Focusing on the development of edge intelligence, Artery continues to strengthen its AT32 ecosystem with AT32 AI Studio, a one-stop edge AI development platform designed to help developers efficiently build and deploy edge AI applications on AT32 MCUs, lower the barriers to AI development, and accelerate the transition from AI models to real-world products.
An Integrated Toolchain Streamlining the Entire Edge AI Development Process
AT32 AI Studio integrates key capabilities throughout the edge AI development process, including data processing, model training and optimization, simulation and validation, and code generation, into a unified development environment. This integration helps developers reduce tool switching and repetitive configuration, enabling more efficient integration of AI models into AT32 MCU applications.
With its graphical development workflow and automated code generation capabilities, developers can build AI applications more intuitively and quickly convert optimized models into embedded code compatible with the AT32 platform, further shortening the development cycle from algorithm validation to product implementation.
Optimized for Edge Computing, Enabling Lightweight AI Model Deployment
For resource-constrained embedded devices, model size, memory usage, computational requirements, and power consumption often directly determine whether AI applications can be successfully deployed.
AT32 AI Studio provides model optimization capabilities tailored to edge deployment requirements. Through techniques such as quantization and compression, the platform reduces model storage and computational resource requirements while maintaining accuracy and improving execution efficiency on AT32 MCUs. In addition, the platform includes lightweight neural network models designed for embedded applications, providing developers with an AI development foundation better suited to the resource constraints of MCUs. These capabilities enable AI algorithms to move beyond basic execution toward practical deployment and real-world applications.
Unlocking the Potential of AT32 Edge AI Across Diverse Applications
AT32 AI Studio has been successfully applied to various scenarios, including voice keyword recognition, Time-of-Flight (ToF)-based gesture recognition, and industrial anomaly detection, demonstrating its versatility. By leveraging AT32 AI Studio, developers can combine AI algorithms with the hardware capabilities of AT32 MCUs to enhance sensing and decision-making capabilities in end devices, expanding the potential of MCU-based applications in smart homes, industrial control, smart wearables, and human-machine interaction.
Focused on Practical Deployment, Bringing AI Development Closer to Real-World Products
For embedded AI applications, successful execution of a model on a PC does not necessarily guarantee stable operation on actual hardware. Model accuracy, resource utilization, and real-world performance must still be validated in the target hardware environment.
AT32 AI Studio incorporates simulation, evaluation, and practical deployment as essential stages of the development process, establishing a complete development–validation–deployment workflow. This approach helps developers thoroughly evaluate model performance on the AT32 platform during development, while automated code generation further facilitates integration with embedded software development.
Empowering the Ecosystem with Development Tools and Accelerating the Transition to Edge Intelligence
As applications evolve from traditional control to intelligent sensing, MCUs are becoming an important platform for extending AI capabilities to end devices. Artery Technology continues to enhance its software ecosystem and development toolchain centered on AT32 MCUs, reducing development complexity, improving model deployment efficiency, and providing developers with more comprehensive and efficient AI development support.
AT32 AI Studio represents an important part of Artery's AI ecosystem development, bridging Physical AI and edge computing. Through an end-to-end development workflow, MCU-oriented model optimization, and automated deployment capabilities, Artery Technology will further unlock the potential of edge AI applications on the AT32 platform, helping developers integrate AI capabilities into end products more efficiently and bringing more intelligent applications from algorithms to reality.
Artery Technology specializes in the research, development, and innovation of 32-bit microcontrollers, providing high-performance, highly reliable products and solutions for a wide range of applications, including industrial control, consumer electronics, IoT, and smart applications. The company is committed to advancing intelligent technologies through continuous innovation.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Artery AT32 AI Studio Empowers Edge Intelligence, Accelerating AI Application Deployment
- Advancing Precision Diagnosis and Treatment
- Photodynamic Therapy Introduced for the First Time into Colposcopy Faculty Training in China
WUHAN, China, Oct. 23, 2026 /PRNewswire/ -- The 2026 CSCCP-ASCCP Colposcopy Training Course, held in Wuhan from October 21 to 23, concluded successfully. Jointly organized by the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) and the American Society for Colposcopy and Cervical Pathology (ASCCP), and co-hosted by Tongji Hospital and Union Hospital, both affiliated with Tongji Medical College of Huazhong University of Science and Technology, the program featured live demonstrations and teaching sessions on representative clinical cases, lectures on foundational principles and the latest advances, interdisciplinary clinical-pathological discussions, and multidisciplinary team (MDT) consultations on challenging cases. Emphasizing precision diagnosis, treatment, and risk-stratified management, the program also marked the first time photodynamic therapy (PDT) had been incorporated into colposcopy faculty training in China, with the PDT training sessions supported by Asieris Pharmaceuticals. This initiative represents a practical contribution to China's efforts to foster a fertility-friendly society and advance the management of cervical lesions toward greater precision and non-invasive treatment.
During the three-day program, more than 60 clinicians specializing in colposcopy and the diagnosis and treatment of cervical lesions from across China completed systematic training and the final examination. The program was conducted under the honorary chairmanship of Professor Ding Ma, Member of the Chinese Academy of Engineering and Chair of the Department of Obstetrics and Gynecology at Tongji Hospital. Professor Peng Wu, Director of the Department of Obstetrics and Gynecology at Union Hospital, served as program lead. Professor Nan Yu, Head of the Cervical Disease Specialty at Tongji Hospital, and Professor Rui Gao of Union Hospital served as course coordinators.
The faculty also included Professor Christine Conageski of the University of Colorado; Professor Chenquan Zhao, University of Pittsburgh Medical Center and Chief Overseas Medical Advisor to CSCCP; Professor Yuxin Liu of the Department of Pathology at the Icahn School of Medicine at Mount Sinai; and Professor Francisco García, Member of the U.S. National Academy of Medicine and former President of ASCCP, among other experts.
Precision Diagnosis and Risk-Stratified Management Throughout the Training Program
The principles of precision diagnosis, treatment, and risk-stratified management were integrated into every component of the program, from procedural demonstrations and theoretical lectures to case-based discussions. During live demonstrations of colposcopy, loop electrosurgical excision procedure (LEEP), laser ablation, and PDT, experts presented cases representing different risk levels, incorporating risk-based decision-making throughout colposcopic assessment, biopsy sampling, and individualized treatment planning.
The didactic sessions covered a comprehensive range of clinical topics. Chinese and U.S. experts discussed triage and management of individuals who test positive for HPV during primary screening; HPV integration empowers precision diagnosis and treatment of cervical lesions; advances in the pathological diagnosis of cervical cancer and precancerous lesions; colposcopy techniques and quality control; standardized colposcopy terminology and reporting; treatment strategies for cervical intraepithelial neoplasia grade 2 (CIN2) based on the latest 2026 U.S. National Cancer Institute data; the development and clinical translation of the world's first trivalent HPV therapeutic vaccine; risk-based colposcopy management; management of positive surgical margins following cervical conization; diagnostic pitfalls in cervical biopsy pathology; colposcopy and fertility preservation in lower genital tract and cervical diseases; the colposcopic identification of cervical glandular lesions; and the diagnosis and treatment of vaginal intraepithelial neoplasia with case sharing; interpretation of the 2026 ISSVD terminology standards for vulvar intraepithelial neoplasia and squamous intraepithelial lesions; and the diagnosis and management of vulvar lichenoid diseases.
From triage following a positive primary HPV screening result to quality assurance in colposcopy, standardized reporting, and the management of positive surgical margins, the program promoted an integrated approach spanning the entire care pathway: screening, triage, diagnosis, treatment, and follow-up.
During the interdisciplinary clinical-pathological and MDT case discussions, Chinese and international experts guided participants through case reviews incorporating pathological findings. In-depth discussions addressed key diagnostic challenges, including concordance between colposcopic impressions and pathological diagnoses, as well as potential pitfalls in cervical biopsy interpretation. These sessions helped participants strengthen their ability to integrate clinical, pathological, and molecular information to support more precise clinical decision-making.
Several participating clinicians noted that this risk-stratified approach to faculty training offered practical guidance for standardizing colposcopy practice, particularly in primary and community-level healthcare settings.
PDT Incorporated into Colposcopy Faculty Training in China for the First Time, Supporting Standardized Non-Invasive Treatment
Another highlight of the program was the first-ever inclusion of PDT in a colposcopy faculty training program in China, with a dedicated curriculum combining theoretical instruction and simulated hands-on practice.
As cervical precancerous lesions are increasingly being diagnosed in younger women, an important clinical challenge is how to effectively treat these lesions while preserving reproductive function in women of childbearing age. Traditional excisional treatments can effectively remove lesions but may increase the risks of adverse pregnancy outcomes, including miscarriage and preterm birth, as well as cervical stenosis.
PDT is a non-excisional, non-invasive treatment approach that uses light-activated photosensitizers to selectively target abnormal cells. It can also help eliminate high-risk human papillomavirus (HPV), offering a treatment option that aims to control lesions while preserving normal cervical anatomy and function. This approach may be particularly relevant for women who wish to preserve their fertility.
PDT has been recommended in relevant expert consensus documents, and a portable cervical PDT technology has been approved in China for the treatment of CIN2. It may be particularly suitable for women who plan to conceive in the near future or who wish to preserve their future reproductive options, subject to individualized clinical assessment.
During the training, experts provided live demonstrations of LEEP, laser ablation, and PDT, enabling participants to observe procedural workflows and the considerations involved in selecting appropriate patients. The curriculum also included sessions on procedural principles and simulated practice in colposcopy, LEEP, laser ablation, and PDT. Under expert supervision, participants practiced the relevant procedures and learned the standardized operating protocols, principles of efficacy assessment, and key considerations for post-treatment follow-up associated with PDT.
A dedicated lecture on colposcopy for lower genital tract and cervical diseases, with a focus on fertility preservation, further reinforced the importance of fertility-conscious clinical decision-making.
The inclusion of PDT in colposcopy faculty training represents a step toward equipping clinicians not only with standardized diagnostic skills but also with training in non-invasive treatment options. By strengthening clinical capabilities across both diagnosis and treatment, the program supports more comprehensive management of cervical lesions while contributing to China's broader efforts to build a fertility-friendly society.
From advancing risk-stratified precision management to pioneering the inclusion of PDT in colposcopy faculty training in China, 2026 CSCCP-ASCCP Colposcopy Training Course—Wuhan Station represented more than a systematic effort to strengthen clinical teaching capabilities. It also marked an important practical step toward more precise, individualized, and non-invasive management of cervical lesions.
WUHAN, China, Oct. 23, 2026 /PRNewswire/ -- The 2026 CSCCP-ASCCP Colposcopy Training Course, held in Wuhan from October 21 to 23, concluded successfully. Jointly organized by the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) and the American Society for Colposcopy and Cervical Pathology (ASCCP), and co-hosted by Tongji Hospital and Union Hospital, both affiliated with Tongji Medical College of Huazhong University of Science and Technology, the program featured live demonstrations and teaching sessions on representative clinical cases, lectures on foundational principles and the latest advances, interdisciplinary clinical-pathological discussions, and multidisciplinary team (MDT) consultations on challenging cases. Emphasizing precision diagnosis, treatment, and risk-stratified management, the program also marked the first time photodynamic therapy (PDT) had been incorporated into colposcopy faculty training in China, with the PDT training sessions supported by Asieris Pharmaceuticals. This initiative represents a practical contribution to China's efforts to foster a fertility-friendly society and advance the management of cervical lesions toward greater precision and non-invasive treatment.
During the three-day program, more than 60 clinicians specializing in colposcopy and the diagnosis and treatment of cervical lesions from across China completed systematic training and the final examination. The program was conducted under the honorary chairmanship of Professor Ding Ma, Member of the Chinese Academy of Engineering and Chair of the Department of Obstetrics and Gynecology at Tongji Hospital. Professor Peng Wu, Director of the Department of Obstetrics and Gynecology at Union Hospital, served as program lead. Professor Nan Yu, Head of the Cervical Disease Specialty at Tongji Hospital, and Professor Rui Gao of Union Hospital served as course coordinators.
The faculty also included Professor Christine Conageski of the University of Colorado; Professor Chenquan Zhao, University of Pittsburgh Medical Center and Chief Overseas Medical Advisor to CSCCP; Professor Yuxin Liu of the Department of Pathology at the Icahn School of Medicine at Mount Sinai; and Professor Francisco García, Member of the U.S. National Academy of Medicine and former President of ASCCP, among other experts.
Precision Diagnosis and Risk-Stratified Management Throughout the Training Program
The principles of precision diagnosis, treatment, and risk-stratified management were integrated into every component of the program, from procedural demonstrations and theoretical lectures to case-based discussions. During live demonstrations of colposcopy, loop electrosurgical excision procedure (LEEP), laser ablation, and PDT, experts presented cases representing different risk levels, incorporating risk-based decision-making throughout colposcopic assessment, biopsy sampling, and individualized treatment planning.
The didactic sessions covered a comprehensive range of clinical topics. Chinese and U.S. experts discussed triage and management of individuals who test positive for HPV during primary screening; HPV integration empowers precision diagnosis and treatment of cervical lesions; advances in the pathological diagnosis of cervical cancer and precancerous lesions; colposcopy techniques and quality control; standardized colposcopy terminology and reporting; treatment strategies for cervical intraepithelial neoplasia grade 2 (CIN2) based on the latest 2026 U.S. National Cancer Institute data; the development and clinical translation of the world's first trivalent HPV therapeutic vaccine; risk-based colposcopy management; management of positive surgical margins following cervical conization; diagnostic pitfalls in cervical biopsy pathology; colposcopy and fertility preservation in lower genital tract and cervical diseases; the colposcopic identification of cervical glandular lesions; and the diagnosis and treatment of vaginal intraepithelial neoplasia with case sharing; interpretation of the 2026 ISSVD terminology standards for vulvar intraepithelial neoplasia and squamous intraepithelial lesions; and the diagnosis and management of vulvar lichenoid diseases.
From triage following a positive primary HPV screening result to quality assurance in colposcopy, standardized reporting, and the management of positive surgical margins, the program promoted an integrated approach spanning the entire care pathway: screening, triage, diagnosis, treatment, and follow-up.
During the interdisciplinary clinical-pathological and MDT case discussions, Chinese and international experts guided participants through case reviews incorporating pathological findings. In-depth discussions addressed key diagnostic challenges, including concordance between colposcopic impressions and pathological diagnoses, as well as potential pitfalls in cervical biopsy interpretation. These sessions helped participants strengthen their ability to integrate clinical, pathological, and molecular information to support more precise clinical decision-making.
Several participating clinicians noted that this risk-stratified approach to faculty training offered practical guidance for standardizing colposcopy practice, particularly in primary and community-level healthcare settings.
PDT Incorporated into Colposcopy Faculty Training in China for the First Time, Supporting Standardized Non-Invasive Treatment
Another highlight of the program was the first-ever inclusion of PDT in a colposcopy faculty training program in China, with a dedicated curriculum combining theoretical instruction and simulated hands-on practice.
As cervical precancerous lesions are increasingly being diagnosed in younger women, an important clinical challenge is how to effectively treat these lesions while preserving reproductive function in women of childbearing age. Traditional excisional treatments can effectively remove lesions but may increase the risks of adverse pregnancy outcomes, including miscarriage and preterm birth, as well as cervical stenosis.
PDT is a non-excisional, non-invasive treatment approach that uses light-activated photosensitizers to selectively target abnormal cells. It can also help eliminate high-risk human papillomavirus (HPV), offering a treatment option that aims to control lesions while preserving normal cervical anatomy and function. This approach may be particularly relevant for women who wish to preserve their fertility.
PDT has been recommended in relevant expert consensus documents, and a portable cervical PDT technology has been approved in China for the treatment of CIN2. It may be particularly suitable for women who plan to conceive in the near future or who wish to preserve their future reproductive options, subject to individualized clinical assessment.
During the training, experts provided live demonstrations of LEEP, laser ablation, and PDT, enabling participants to observe procedural workflows and the considerations involved in selecting appropriate patients. The curriculum also included sessions on procedural principles and simulated practice in colposcopy, LEEP, laser ablation, and PDT. Under expert supervision, participants practiced the relevant procedures and learned the standardized operating protocols, principles of efficacy assessment, and key considerations for post-treatment follow-up associated with PDT.
A dedicated lecture on colposcopy for lower genital tract and cervical diseases, with a focus on fertility preservation, further reinforced the importance of fertility-conscious clinical decision-making.
The inclusion of PDT in colposcopy faculty training represents a step toward equipping clinicians not only with standardized diagnostic skills but also with training in non-invasive treatment options. By strengthening clinical capabilities across both diagnosis and treatment, the program supports more comprehensive management of cervical lesions while contributing to China's broader efforts to build a fertility-friendly society.
From advancing risk-stratified precision management to pioneering the inclusion of PDT in colposcopy faculty training in China, 2026 CSCCP-ASCCP Colposcopy Training Course—Wuhan Station represented more than a systematic effort to strengthen clinical teaching capabilities. It also marked an important practical step toward more precise, individualized, and non-invasive management of cervical lesions.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
2026 CSCCP-ASCCP Colposcopy Training Course--Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions
